Asia Pacific Non-Alcoholic Steatohepatitis Market

The Asia Pacific non-alcoholic steatohepatitis market is expected to reach US$ 4,040.30 million by 2028 from US$ 216.54 million in 2021. The market is estimated to grow at a CAGR of 51.9% from 2021 to 2028.

The rising prevalence of Non-Alcoholic Steatohepatitis is expected to grow the opportunities for research & development of Non-Alcoholic Steatohepatitis diagnostics and management in developing nations. Leading market players increased their penetration across emerging markets by growing their distribution networks and augmented manufacturing capabilities. Emerging markets in India and South Korea are expected to offer potential growth opportunities for crucial non-alcoholic steatohepatitis (NASH) manufacturers in the coming years due to the large patient population; high prevalence of lifestyle diseases, such as obesity, diabetes, low HDL cholesterol, high lipids, and high blood pressure; increasing disposable income; improving healthcare infrastructure; and growing medical tourism in the above-mentioned countries. Asia Pacific is a business-friendly and adaptable hub due to relatively less stringent regulations and data requirements.The Asia Pacific non-alcoholic steatohepatitis market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Non-Alcoholic Steatohepatitis Revenue and Forecast to 2028 (US$ Million)  

Asia Pacific Non-Alcoholic Steatohepatitis Market Segmentation         

The Asia Pacific non-alcoholic steatohepatitis market is segmented into product, application, sales channel, and country. Based on product type, the Asia Pacific non-alcoholic steatohepatitis  market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period.Based on application, the Asia Pacific non-alcoholic steatohepatitis market is segmented into treatment and diagnosis. The treatment segment dominated the Asia Pacific non-alcoholic steatohepatitis market in 2020. Based on sales channel, the Asia Pacific non-alcoholic steatohepatitis market is segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment dominated the Asia Pacific non-alcoholic steatohepatitis market in 2020. Based on country, the Asia Pacific non-alcoholic steatohepatitis market is segmented into China, Japan, India, Australia, South Korea, Rest of Asia-Pacific. China dominated the Asia Pacific non-alcoholic steatohepatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, Siemens Healthineers AG, and Laboratory Corporation of America Holdings are among the leading companies in the Asia Pacific non-alcoholic steatohepatitis market